New hope for patients with rare lung cancer transformation
NCT ID NCT07414927
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called BL0020 in 48 adults whose lung cancer has changed from one type (non-small cell) to another (small cell) after standard treatment. The drug is given by IV every three weeks. The goal is to see if it can shrink tumors and control the disease in people who have no other standard options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BL0020 (a polymer-drug conjugate containing the chemotherapy agent SN-38)
What this could lead to
If successful, this could provide a new treatment option for patients with a rare and aggressive form of lung cancer that currently has no standard therapy.
What could go wrong
This is an early-phase trial with only 48 participants, so results may not apply broadly. The drug may cause side effects typical of chemotherapy, and it is not yet known if it will improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL CARCINOMA OF LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Chest Hospital
Shanghai, 200030, China
Contact
Contact